How does MRSA bacteremia affect long-term patient outcomes. What are the mortality rates associated with MRSA bloodstream infections. Which factors influence survival prognosis for patients with MRSA bacteremia. How can clinicians improve long-term outcomes for MRSA bacteremia patients.

Understanding MRSA Bacteremia: A Serious Bloodstream Infection

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a severe bloodstream infection caused by antibiotic-resistant Staphylococcus aureus bacteria. This condition poses significant challenges in healthcare settings due to its resistance to many commonly used antibiotics.

MRSA bacteremia can lead to serious complications, including endocarditis, osteomyelitis, and sepsis. The infection’s ability to spread rapidly through the bloodstream makes it particularly dangerous, especially for vulnerable populations such as the elderly, immunocompromised individuals, and those with underlying health conditions.

Mortality Rates Associated with MRSA Bacteremia

Mortality rates for MRSA bacteremia remain concerningly high, despite advancements in medical care and antibiotic treatments. Studies have shown that the 30-day mortality rate for MRSA bacteremia can range from 20% to 30%, with some reports indicating even higher rates in certain patient populations.

The long-term prognosis for patients who survive the initial infection is also a subject of ongoing research. Some studies suggest that survivors of MRSA bacteremia may face increased risk of mortality for up to a year after the initial infection, highlighting the need for continued monitoring and care.

Factors Influencing Mortality Rates

• Patient age and overall health status
• Presence of underlying medical conditions
• Timeliness of diagnosis and initiation of appropriate antibiotic therapy
• Source of infection (e.g., central line-associated vs. community-acquired)
• Severity of sepsis or other complications at the time of diagnosis
• Antibiotic resistance patterns of the infecting MRSA strain

Risk Factors for Poor Long-Term Outcomes in MRSA Bacteremia

Identifying risk factors for poor long-term outcomes in MRSA bacteremia patients is crucial for developing targeted interventions and improving prognosis. Research has highlighted several key factors that may contribute to increased mortality risk:

1. Advanced age (>65 years)
2. Immunosuppression
3. Presence of prosthetic devices or implants
4. Persistent bacteremia despite appropriate antibiotic therapy
5. Development of metastatic infections
6. Inadequate source control (e.g., failure to remove infected catheters)
7. Delayed initiation of appropriate antibiotic treatment

Understanding these risk factors can help healthcare providers identify high-risk patients and implement more aggressive treatment strategies to improve outcomes.

Improving Long-Term Outcomes for MRSA Bacteremia Patients

Enhancing the long-term prognosis for patients with MRSA bacteremia requires a multifaceted approach. Healthcare providers and researchers are continually working to develop strategies to improve patient outcomes and reduce mortality rates.

Early Detection and Rapid Diagnosis

Early detection of MRSA bacteremia is crucial for improving patient outcomes. Rapid diagnostic techniques, such as polymerase chain reaction (PCR) testing, can help identify MRSA infections more quickly than traditional culture methods. This allows for earlier initiation of appropriate antibiotic therapy, which is associated with improved survival rates.

Optimal Antibiotic Management

Selecting the most appropriate antibiotic regimen is essential for effectively treating MRSA bacteremia. Vancomycin has long been considered the gold standard treatment, but newer antibiotics like daptomycin and ceftaroline have shown promise in certain clinical scenarios. Tailoring antibiotic therapy based on the patient’s specific situation, including the source of infection and the organism’s susceptibility profile, can help optimize treatment outcomes.

Source Control and Management of Complications

Identifying and addressing the source of MRSA bacteremia is crucial for successful treatment. This may involve removing infected catheters or draining abscesses. Additionally, prompt management of complications such as endocarditis or osteomyelitis is essential for improving long-term outcomes.

The Role of Antimicrobial Stewardship in MRSA Bacteremia Management

Antimicrobial stewardship programs play a vital role in improving outcomes for patients with MRSA bacteremia. These programs aim to optimize antibiotic use, reduce the development of antibiotic resistance, and improve patient outcomes.

Key aspects of antimicrobial stewardship in MRSA bacteremia management include:

• Ensuring appropriate empiric antibiotic selection
• Promoting timely de-escalation of broad-spectrum antibiotics when possible
• Monitoring therapeutic drug levels (e.g., vancomycin trough levels)
• Encouraging appropriate duration of therapy
• Facilitating transitions from intravenous to oral antibiotics when appropriate

By implementing these strategies, healthcare facilities can help reduce the incidence of MRSA bacteremia and improve outcomes for affected patients.

Emerging Treatment Options for MRSA Bacteremia

As antibiotic resistance continues to pose challenges in treating MRSA bacteremia, researchers are exploring new treatment options to improve patient outcomes. Several promising approaches are currently under investigation:

Novel Antibiotics

New antibiotics with activity against MRSA are being developed and tested. These include drugs like tedizolid, which has shown efficacy against MRSA in clinical trials, and newer agents in the pipeline that target specific mechanisms of bacterial resistance.

Combination Therapy

Combining different antibiotics may offer synergistic effects against MRSA. For example, some studies have explored the combination of vancomycin with beta-lactam antibiotics, showing potential improvements in bacterial clearance and clinical outcomes.

Immunomodulatory Approaches

Researchers are investigating the potential of immunomodulatory therapies to enhance the body’s natural defense mechanisms against MRSA. This includes exploring the use of monoclonal antibodies and other immune-enhancing agents as adjunctive treatments to antibiotics.

Bacteriophage Therapy

The use of bacteriophages – viruses that specifically target and kill bacteria – is gaining interest as a potential treatment for antibiotic-resistant infections like MRSA. While still in early stages of research for MRSA bacteremia, this approach shows promise as a novel therapeutic strategy.

Long-Term Follow-Up and Monitoring of MRSA Bacteremia Survivors

Improving the long-term prognosis of MRSA bacteremia patients extends beyond the initial treatment phase. Implementing comprehensive follow-up and monitoring strategies is crucial for detecting and addressing potential complications or recurrences.

Post-Discharge Surveillance

Regular follow-up appointments and blood tests can help detect early signs of infection recurrence or the development of complications. This is particularly important in the first year following the initial infection, when the risk of adverse outcomes remains elevated.

Screening for Persistent Colonization

Some patients may remain colonized with MRSA after successful treatment of bacteremia. Screening for persistent colonization can help guide decolonization efforts and reduce the risk of recurrent infections.

Addressing Long-Term Consequences

MRSA bacteremia survivors may experience long-term physical and psychological effects. These can include persistent fatigue, cognitive impairment, and post-traumatic stress disorder. Comprehensive follow-up care should address these potential issues and provide appropriate support and interventions.

The Impact of Hospital-Wide MRSA Prevention Strategies on Bacteremia Outcomes

Implementing effective MRSA prevention strategies at the hospital level can significantly impact the incidence and outcomes of MRSA bacteremia. Several key approaches have shown promise in reducing MRSA transmission and infection rates:

Active Surveillance

Screening high-risk patients for MRSA colonization upon hospital admission allows for early identification and implementation of appropriate precautions. This can help prevent the spread of MRSA within healthcare facilities and reduce the risk of subsequent bacteremia.

Contact Precautions

Implementing strict contact precautions for patients colonized or infected with MRSA, including the use of gowns and gloves by healthcare workers, can help minimize transmission. However, the optimal duration and scope of these precautions remain subjects of ongoing debate and research.

Hand Hygiene Initiatives

Improving hand hygiene compliance among healthcare workers is a cornerstone of MRSA prevention. Implementing comprehensive hand hygiene programs, including education, monitoring, and feedback, can significantly reduce MRSA transmission rates.

Environmental Cleaning and Decontamination

Thorough cleaning and disinfection of patient rooms and high-touch surfaces are crucial for preventing the spread of MRSA. Some facilities have explored the use of advanced technologies like ultraviolet light disinfection to enhance traditional cleaning methods.

By implementing these hospital-wide prevention strategies, healthcare facilities can reduce the overall burden of MRSA infections, potentially leading to improved outcomes for patients who do develop MRSA bacteremia.

Future Directions in MRSA Bacteremia Research and Management

As the medical community continues to grapple with the challenges posed by MRSA bacteremia, several areas of research and development hold promise for improving long-term prognosis and patient outcomes:

Personalized Treatment Approaches

Advances in genomic sequencing and biomarker identification may allow for more personalized treatment strategies. By understanding individual patient factors and characteristics of the infecting MRSA strain, clinicians may be able to tailor antibiotic regimens and supportive care more effectively.

Improved Diagnostics

Developing faster, more accurate diagnostic tools for MRSA detection and antibiotic susceptibility testing can help guide treatment decisions more quickly. This includes exploring the potential of machine learning algorithms to predict antibiotic resistance patterns based on clinical and laboratory data.

Novel Therapeutic Targets

Ongoing research into the molecular mechanisms of MRSA virulence and antibiotic resistance may uncover new therapeutic targets. This could lead to the development of innovative treatment approaches that go beyond traditional antibiotic therapy.

Enhanced Prevention Strategies

Continued research into MRSA transmission dynamics and risk factors can inform the development of more effective prevention strategies. This may include exploring the potential of MRSA vaccines or novel decolonization approaches to reduce the risk of infection in high-risk populations.

As research in these areas progresses, the hope is that long-term outcomes for patients with MRSA bacteremia will continue to improve, reducing mortality rates and enhancing quality of life for survivors.

Long-Term Prognosis of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia at a Tertiary Care Hospital in the United States (US) | Open Forum Infectious Diseases

Navbar Search Filter

Open Forum Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Mobile Enter search term

Close

Navbar Search Filter

Open Forum Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Enter search term

Advanced Search

Journal Article

Alexander J Lepak, MD,

Alexander J Lepak, MD

Search for other works by this author on:

Oxford Academic

Google Scholar

Meghan Brennan, MD,

Meghan Brennan, MD

Search for other works by this author on:

Oxford Academic

Google Scholar

Joseph McBride, MD,

Joseph McBride, MD

Search for other works by this author on:

Oxford Academic

Google Scholar

Erin McCreary, PharmD, BCPS,

Erin McCreary, PharmD, BCPS

Search for other works by this author on:

Oxford Academic

Google Scholar

Derrick Chen, MD

Derrick Chen, MD

Search for other works by this author on:

Oxford Academic

Google Scholar

Author Notes

Open Forum Infectious Diseases, Volume 4, Issue suppl_1, Fall 2017, Page S565, https://doi. org/10.1093/ofid/ofx163.1477

Published:

04 October 2017

Navbar Search Filter

Open Forum Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Mobile Enter search term

Close

Navbar Search Filter

Open Forum Infectious DiseasesThis issueIDSA JournalsInfectious DiseasesBooksJournalsOxford Academic
Enter search term

Advanced Search

Abstract

Background

MRSA bacteremia is associated with high short-term mortality (20–30%), however little is known about the long-term prognosis. Two small studies outside the US have demonstrated significant trends in decreased survival up to one year from a SA bacteremia episode, although the number of MRSA isolates in these studies was very small. We therefore sought to examine the 1 year prognosis in adult patients admitted to a tertiary care hospital in the US with MRSA bacteremia.

Methods

All patients age ≥18 y.o. admitted to the University of Wisconsin Hospital (UWHC) with MRSA isolated from a blood culture were identified from 2014 to May of 2016. A retrospective chart review was performed for data extraction including demographic, medical comorbidities, microbiological results, therapeutic decisions, and outcomes including short- (30 d) and long-term (1 year) survival. Date of death was documented for a majority of patients seen at UWHC in our EMR. A search of publicly available obituaries was performed to clarify survival for those patients without a documented death and lack of current clinical notes in the EMR.

Results

The total number of MRSA bacteremias in adult patients at UWHC over the period was 69. Demographic Results. Male 59%, ≥65 y.o. 33%, active malignancy 26%, transplantation 14%, diabetes 39%, cardiovascular disease 49%, living at home prior to admission 71%, previous hospitalization (90 d) 62%. A removable source (i.e., line) was the source in 14%, evidence of sepsis requiring ICU admission was present in 36%, and disseminated infection documented in 22%. Vancomycin was used as initial therapy in 96% of patients and empirically started prior to known culture results in 77%. Only 14 patients (20%) had an MIC of 2 mg/L to vancomycin. The all cause 30 d mortality was 25% and 1 year mortality was 48%. The Kaplan-Meier survival curve is shown. On univariate analysis, only ICU admission was significantly associated with mortality.

Open in new tabDownload slide

Conclusion

Nearly 50% of patients with MRSA bacteremia at our institution did not survive one year. This represents a doubling of the 30 d mortality in our study suggesting there is significant ongoing mortality risk outside of the traditional short-term period. We plan to gather additional data to perform a multivariate analysis.

Disclosures

All authors: No reported disclosures.

This content is only available as a PDF.

Author notes

Session: 232. Clinical: Bacteremia and Endocarditis

Saturday, October 7, 2017: 12:30 PM

© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected]

Issue Section:

Poster Abstract

Download all slides

Advertisement

Citations

Altmetric

More metrics information

Email alerts

Article activity alert

Advance article alerts

New issue alert

In progress issue alert

Receive exclusive offers and updates from Oxford Academic

Citing articles via

• 
  

  
  Latest
  

• 
  

  
  Most Read
  

• 
  

  
  Most Cited
  

Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients with COVID-19 Using Nationwide Real-World Data: An Observational Matched Cohort Study from The Japan COVID-19 Task Force

Eradicating Pulmonary Mycobacterium Abscessus (Mab): The Promise of Dual β-Lactam Therapy

Comparing 7 vs 6-8 Day Penicillin Treatment Intervals Among Pregnant People with Syphilis of Late or Unknown Duration: No Difference Found in Incidence of Congenital Syphilis

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials

Maternal breast milk secretor phenotype does not affect infant susceptibility to rotavirus diarrhea

Autopsy Pathologist and CLIA Medical Director Leadership Opportunity University of Vermont Health Network

, Vermont

ACADEMIC SURGICAL PATHOLOGIST

, Vermont

MEDICAL MICROBIOLOGY AND CLINICAL LABORATORY MEDICINE PHYSICIAN

, Vermont

CLINICAL CHEMISTRY LABORATORY MEDICINE PHYSICIAN

, Vermont

View all jobs

Advertisement

MRSA The Super Bug – Prognosis / Complications

Written by Dr. Reeja Tharu, M.Phil.,Ph.D

Medically Reviewed by Dr. Sunil Shroff, MBBS, MS, FRCS (UK), D. Urol (Lond)

Last Updated on Oct 12, 2020

Prognosis / Complications

Current statistics reveal that approximately 1.2 million hospitalized patients are MRSA-infected. The mortality rate is roughly estimated to be between 4%-10% while another study says that it may be as high as 23%.

Thankfully the infection is not very high (roughly 1%) in hospitalized children below age 18, as opposed to adults, despite the fact their number has markedly increased over the years.

CA-MRSA has far less complications than HA-MRSA, especially if the patient responds well to treatment and is not in need of hospitalization.

Early diagnosis and treatment is important if the patient is to avoid complications associated with MRSA-infection. If the patient develops complications such as endocarditis, kidney or lung infections, necrotizing fasciitis, osteomyelitis, or sepsis the outcome may not be very encouraging as they lead to irreversible organ damage.

Published on Jun 01, 2010
Last Updated on Oct 12, 2020

i Sources

Cite this Article

Medindia adheres to strict ethical publishing standards to provide accurate, relevant, and current health content. We source our material from reputable places such as peer-reviewed journals, academic institutions, research bodies, medical associations, and occasionally, non-profit organizations. We welcome and value audience feedback as a part of our commitment to health literacy and informed decision-making.

1. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) – Mark C. Enright D. Ashley Robinson, Gaynor Randle, Edward J. Feil, Hajo Grundmann, and Brian G. Spratt.

Please use one of the following formats to cite this article in your essay, paper or report:

• APA

  Dr. Reeja Tharu. (2020, October 12). MRSA The Super Bug – Prognosis / Complications. Medindia. Retrieved on Jun 10, 2023 from https://www.medindia.net/patients/patientinfo/mrsa-prognosis-complications.htm.

• MLA

  Dr. Reeja Tharu. “MRSA The Super Bug – Prognosis / Complications”. Medindia. Jun 10, 2023. <https://www.medindia.net/patients/patientinfo/mrsa-prognosis-complications.htm>.

• Chicago

  Dr. Reeja Tharu. “MRSA The Super Bug – Prognosis / Complications”. Medindia. https://www.medindia.net/patients/patientinfo/mrsa-prognosis-complications.htm. (accessed Jun 10, 2023).

• Harvard

  Dr. Reeja Tharu. 2020. MRSA The Super Bug – Prognosis / Complications. Medindia, viewed Jun 10, 2023, https://www.medindia.net/patients/patientinfo/mrsa-prognosis-complications.htm.

<< Treatment

Tips to Prevent MRSA Infection >>

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.

Antibiotic crash and heavy-duty metal: Industry Digest 4.0 No. 16

Topic of the week: development of new antibiotics

An international team of scientists commissioned by the British government analyzed the resistance of pathogenic bacteria to antibiotics. By 2050, these dangerous microorganisms will kill 10 million people a year, according to her research. Now every year, 700,000 people die from diseases caused by bacteria. The main reason for the appearance of supermicrobes that are resistant to several antibiotics at once is the uncontrolled and unreasonable use of these drugs. Including their widespread use in agriculture. As a result, the bacteria mutate and stop responding to antibiotics.

New drugs are expensive to develop and active ingredients are difficult to find. So one strategy is to look for ways to make existing antibiotics more powerful. When a microorganism becomes resistant to a drug, it produces special enzymes that break down the drug. Scientists from the University of Tromsø in Norway found out that they contain zinc. Now they are looking for suitable inhibitors – substances that can react with zinc and block enzymes. The researchers have two candidates, inhibitors 2b and ZN148.

Scientists at Emory University in the US are also looking for compounds that could make antibiotics more effective. To do this, they propose to use an extract of the leaves of the American beautiful carp. Researchers have found that this substance reduces the growth of MRSA, a subspecies of Staphylococcus aureus that causes sepsis. The researchers want to create a drug based on the plant extract and the antibiotic oxacillin, to which MRSA bacteria are resistant.

The development of antibiotic supplements is a temporary solution because bacteria quickly adapt to them. A new way to fight can be the impact on the genes of microbes. So, employees of the Canadian McGill University studied E. coli and found in it special organelle compartments that are responsible for DNA replication. Scientists believe that their discovery will help create drugs that will act on organelles and weaken bacteria.

Another important issue is how to prevent superbugs from passing on their antibiotic resistance genes. This will help modern methods of wastewater treatment. Researchers at Rice University in the US have developed a system that kills bacteria and their genes left in the water. At the heart of the solution are nanospheres of bismuth, carbon and oxygen wrapped in graphene. When exposed to light, they are converted into reactive oxygen species, which kill pathogens.

Development of the week

Scientists from the UK and Germany have created a metal that cannot be cut

Researchers from the University of Durham in the UK and the Fraunhofer Institute in Germany have created a metal that cannot be cut or severely damaged. The development was called Proteus. According to Stefan Shinishevsky, one of the creators of the new material, the scientists were inspired by sea shells. They are thin, but due to their structure they are very durable.

Proteus consists of small ceramic balls that are inside foam metal. It differs from ordinary metal in a shape similar to honeycombs. When the Proteus are cut, the spheres vibrate and turn the energy of the knife or drill against them. Because of this, they become dull. During the experiment, Proteus was unable to cut with an angle grinder, drill, and water jet cutter. The creators of the new material believe that it can be used to make, for example, protective equipment, bank vault doors or bicycle locks.

Case of the week

How AI is helping dermatologists

In 2019, The Lancet published an article about an experiment where AI competed with doctors. People and the computer had to determine from the photo what type of moles on the skin are. It turned out that the algorithm is no worse than doctors can make a diagnosis. And in the case of actinic keratosis, dark spots that appear on the skin due to long exposure to the sun, AI did better than humans.

After the experiment, the scientists analyzed the operation of the computer and found that the algorithm pays attention not to moles and spots, but to the skin around them. It turned out that artificial intelligence is trying to understand whether changes in the body are caused by solar activity. In 2020, Harold Kittler from the Medical University of Vienna conducted a new test. This time, the participants were asked to look not only at the moles, but also at the skin around them when making a diagnosis. Compared to 2019, doctors were 30% better at recognizing actinic keratosis. The researchers concluded that AI can be a good “partner” for dermatologists, but will not completely replace them. To prescribe the right treatment, doctors not only determine the type of moles, but also collect a large amount of disparate information about the patient. The computer does not yet know how to do this.

However, trained algorithms will allow doctors to look at diagnostics in a new way. Doctors will also be able to make a more accurate and faster diagnosis after the algorithms suggest the most likely causes of changes in the skin and calculate the likelihood that the mole is malignant.

Study of the week

UK scientists learn how to predict drought ten weeks in advance

University of Sussex researchers have applied astrophysics to better predict drought. They developed the Astrocast system, which analyzes images from space telescopes. The solution works based on the Vegetation Condition Index. This indicator evaluates how well trees and grasses reflect and absorb light waves. Thus, a healthy plant absorbs red light and reflects near-infrared. If the opposite is true, then the plant is sick. In desert regions, this is an indicator of drought. The Astrocast system constantly analyzes the Vegetation Condition Index and compares its value with the previous ones. With its help, scientists can predict a drought 2.5 months before it starts. This will allow you to better prepare for a disaster.

Single line

• The Japanese company Donut Robotics has released a mask that can translate from eight languages.

• Scientists from the USA have developed a bracelet with which you can interact with augmented reality.

• Robots taught “common sense”.

• American scientists have developed glasses that help color blind people to distinguish colors.

• German Bionic introduced a lightweight carbon exoskeleton.

• Japanese company Kawasaki Heavy Industries Ltd. has created a submarine-drone that will run on resin batteries.

• American researchers have found a way to make fuel from sea water.

What to listen to

An episode of Wired’s Gadget Lab podcast about the present and future of streaming services. The presenters reminisce about how the first companies in the field, such as Netflix, appeared, and talk about how streaming has influenced our perception of culture and how not to get confused by the variety of content and platforms.

What to see

Shane Wyton, engineer and host of Stuff Made Here, created a robot hairdresser during quarantine. He not only cuts his hair evenly, but also knows how to keep up small talk. Sensors and artificial intelligence help him in this. Viton tested the invention on himself, the result of the experiment can be seen in the video.

What to read

Longread about how international companies are developing fully autonomous passenger aircraft. The first solutions have already appeared. Thanks to them, you can land the plane in emergency situations, for example, if the pilot has a stroke. Skeptics believe that this technology will not replace professional pilots. Airbus and Boeing do not agree with them. Both companies are developing their own solutions and see autonomous aircraft as the future.

Subscribe to the RBC Trends Telegram channel and stay up to date with current trends and forecasts about the future of technology, economics, education and innovation.

Gangrene – Symptoms, diagnosis and treatment

Last viewed: 10 May 2023

Last updated: 07 August 2020

Gangrene is a complication of necrosis and is characterized by the breakdown of body tissues. Occurs as a result of ischemia, infection or trauma (or a combination of these processes).

Two main categories: infectious gangrene (which includes necrotizing fasciitis and gas gangrene) and ischemic gangrene (which may result from arterial or venous obstruction).

Risk factors include diabetes, smoking, atherosclerosis, kidney disease, drug and alcohol abuse, malignancy, abdominal trauma or surgery, infected wounds, malnutrition, a hypercoagulable state, prolonged use of hemostatic tourniquets, and community-acquired MRSA infection.

Successful treatment of infectious gangrene requires early diagnosis of the pathology and a combination of extensive surgical debridement, intravenous administration of appropriate antibiotics, and intensive supportive care.

Ischemic gangrene requires revascularization of areas of obstruction and thromboembolism, along with adequate treatment of the underlying disease. Measures to prevent the development of superinfection should also be implemented.

The prognosis of treatment is variable and includes the possibility of worsening of the disease and death.

Definition

Gangrene is a complication of necrosis and is characterized by the breakdown of body tissues. There are two main categories: infectious gangrene (wet gangrene) and ischemic gangrene (dry gangrene). Pathology may be a consequence of ischemia, infection, or trauma (or a combination of these processes). Ischemia may develop as a result of arterial or venous disorders, and may occur in the form of an acute or chronic pathological process (or a combination of signs of both). Critical circulatory disorders are the most common cause of gangrene and are often associated with the pathology of diabetes and the consequences of long-term smoking.